Current management and perspectives for HCV recurrence after liver transplantation

@article{Coilly2013CurrentMA,
  title={Current management and perspectives for HCV recurrence after liver transplantation},
  author={Audrey Coilly and Bruno Roche and Didier Samuel},
  journal={Liver International},
  year={2013},
  volume={33}
}
Hepatitis C virus (HCV) infection is one of the leading causes of end‐stage liver disease and the main indication for liver transplantation (LT) in most countries. All patients who undergo LT with detectable serum HCV RNA experience graft reinfection. Between 20 and 30% of patients develop cirrhosis within 5 years post‐LT. The outcome of transplant patients with cirrhosis on the graft is severe, with a rate of decompensation at 1 year of around 40%. To date, retransplantation is the only option… Expand
Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals
TLDR
The preliminary results of the use of second generation direct acting antivirals in transplant patients showed better efficacy with an SVR rate >70%, and the pre‐ and post‐transplantation safety profile is good. Expand
Risk factors and management of hepatitis C recurrence after liver transplantation
Introduction Liver disease associated with Hepatitis C virus infection is the most common indication for liver transplantation. Patients with detectable hepatitis C virus ribonucleic acid at the timeExpand
Management of post transplant hepatitis C in the direct antiviral agents era
TLDR
Preliminary results in transplant patients showed better efficacy, better tolerability and less drug–drug interactions in antiviral C therapy, leading to SVR rates over 90 % in phase II and III clinical trials, without PEG-IFN and/or RBV. Expand
Direct Antiviral Agents for the Treatment of Hcv Reinfection after Liver
TLDR
The use of DAAs in HCV liver transplanted patients cannot be recommended until well designed large clinical studies will be performed, and the results are largely inconclusive or even anecdotal. Expand
Management of viral hepatitis in liver transplant recipients
TLDR
The recent management and therapeutic approaches of viral hepatitis in liver transplant recipient and direct acting antivirals such as protease inhibitors, polymerase or other non-structural proteins inhibitors are anticipated to establish the new standard of care for transplant recipients. Expand
Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
TLDR
Older donor age and prolonged warm ischaemia time are independent predictors of HCV recurrence after LDLT, and early treatment with the direct-acting sofosbuvir is helpful in resolving the problem of post-LT HCVRecurrence. Expand
New Insights in Recurrent HCV Infection after Liver Transplantation
TLDR
The aim of this paper is to review several specific aspects regarding HCV re-infection after transplant: risk factors, current therapeutics for HCV in different stages of liver transplantation, cellular function of HCV proteins, and molecular mechanisms ofHCV entry. Expand
Interferon-free regimens in the liver-transplant setting.
TLDR
There are some issues that need to be addressed in the peri-LT setting of IFN-free regimens in patients with advanced cirrhosis and portal hypertension, pharmacokinetics of new antivirals in Patients with several grades of hepatic or renal impairment, and drug-drug interactions. Expand
Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
TLDR
In the transplant setting it is also relevant to learn which strategy is most cost-effective in minimizing the negative impact of hepatitis C: preventing graft infection by treating patients before transplantation or treating hepatitis C recurrence after LT. Expand
[HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
TLDR
The preliminary results show high EVR response rates of TVR-based triple therapy in LTx patients with HCV-GT1 re-infection, and immune suppression was tightly monitored, and side effects were reversible. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Antiviral Treatment of Recurrent Hepatitis C After Liver Transplantation: Predictors of Response and Long-Term Outcome
TLDR
Antiviral therapy of recurrent hepatitis C after liver transplantation is able to clear HCV in half the patients, more likely on CsA than on tacrolimus, and markedly improves outcome. Expand
Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up
TLDR
The analysis of causes leading to graft failure in patients with HCV showed that HCV recurrence is responsible for one of three deaths in HCV-positive patients, and new antiviral treatments, as well as adapted immunosuppressive protocols, will be necessary to further improve the outcome of HCV -positive patients after liver transplantation. Expand
Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis
  • B. Roche, M. Sebagh, +7 authors D. Samuel
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2008
TLDR
Fibrosis stage ≥3 was associated with a high rate of liver failure, arguing for an early introduction of antiviral therapy, and EVR is independently associated with SVR. Expand
Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation
TLDR
The natural history of clinically compensated HCV‐graft cirrhosis is shortened when compared with immunocompetent patients, and if retransplantation is considered, it should be performed promptly once decompensation develops. Expand
Long-term outcome of hepatitis C infection after liver transplantation.
TLDR
After liver transplantation for HCV-related cirrhosis, persistent HCV infection can cause severe graft damage, and such damage is more frequent in patients infected with HCV genotype 1b than with other genotypes. Expand
Predictors of patient and graft survival following liver transplantation for hepatitis C
TLDR
While long‐term patient and graft survival following liver transplantation for end‐stage liver disease secondary to HCV are generally comparable with that of most other indications, higher pretransplantationHCV‐RNA titers are strongly associated with poor survival among HCV‐infected recipients. Expand
Liver transplantation for HCV‐associated liver cirrhosis: Predictors of outcomes in a population with significant genotype 3 and 4 distribution
  • A. Zekry, P. Whiting, +5 authors G. McCaughan
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2003
TLDR
In a population of HCV liver transplant recipients with a heterogeneous genotype distribution, donor age, and genotype 4, were predictors of a worse outcome, whereas genotype 3 was associated with a more favorable outcome. Expand
Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation
  • M. Cescon, G. Grazi, +7 authors A. Pinna
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2009
TLDR
The type of immunosuppression during AVT may predict SVR in patients treated for HCV recurrence after liver transplantation (LT), and the rate of AVT discontinuation due to side effects was similar between groups. Expand
Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
  • M. Berenguer, A. Palau, +5 authors J. Berenguer
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2006
TLDR
In conclusion, the efficacy of pegIFN‐Rbvr is similar to the non‐transplant population, and an EVR at 3 months is useful to predict lack of response. Expand
Contribution of donor age to the recent decrease in patient survival among HCV‐infected liver transplant recipients
Recurrent hepatitis occurs in the majority of patients undergoing liver transplantation for hepatitis C virus (HCV) cirrhosis, with progression to cirrhosis in up to 30% after 5 years. Based on theseExpand
...
1
2
3
4
5
...